ArticleHuman genomics2026
Characterizing MEFV gene variants in Jordanian patients with Familial Mediterranean Fever.
Article in Human genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFamilial Mediterranean Fever (FMF) is inherited as an autosomal recessive autoinflammatory disorder caused by mutations in the Mediterranean fever (MEFV) gene and predominantly affects populations from the Mediterranean region. Despite its clinical significance, data regarding the genetic profile of FMF in Jordan remain limited. This study aimed to determine the frequency and pattern of commonly screened MEFV gene variants in a cohort of Jordanian patients clinically diagnosed with Familial Mediterranean Fever.
methodsA retrospective study was conducted on 366 patients aged 12-18 years who fulfilled the Turkish clinical diagnostic criteria for FMF and were treated at Prince Hamza Hospital between October 2022 and December 2023. The Diagnosis was supported by laboratory investigations and inflammatory markers, followed by genetic screening for most common mutations for the MEFV gene. Ethical approval was obtained, and informed consent was provided by legal guardians. Genetic and clinical data were analyzed using SPSS version 23 and the R Studio program.
resultsOut of 366 individuals tested for MEFV gene mutations, 195 (53.3%) were mutation-positive and met the clinical criteria for FMF. The cohort comprised 75% males and 25% females, with a mean age of 13 ± 3 years and a mean age at symptom onset of 11 ± 4 years. The most frequently identified mutation was E148Q (25.12%), predominantly in the heterozygous state, followed by V726A (21.54%) and M694V (22.05%), which were also mainly heterozygous. M694I demonstrated the highest rate of homozygosity (29.41%), while K695R was detected exclusively in the homozygous form. The I692del mutation was not identified in any patient.
conclusionThis study provides baseline data on the frequency of commonly screened MEFV gene variants in Jordanian adolescents with FMF. E148Q, V726A, and M694V were the most frequent mutations, mainly in the heterozygous state, reflecting genetic heterogeneity in the study cohort. Further large-scale studies are warranted to elucidate genotype-phenotype correlations and refine diagnostic and management strategies for FMF in Jordan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.